Name | Number of supported studies | Average coverage | |
---|---|---|---|
oligodendrocyte | 10 studies | 30% ± 11% | |
astrocyte | 9 studies | 31% ± 14% | |
endothelial cell | 8 studies | 28% ± 8% | |
oligodendrocyte precursor cell | 7 studies | 25% ± 8% | |
macrophage | 6 studies | 27% ± 7% | |
microglial cell | 6 studies | 22% ± 5% | |
GABAergic neuron | 5 studies | 43% ± 17% | |
interneuron | 5 studies | 38% ± 20% | |
glutamatergic neuron | 4 studies | 47% ± 17% | |
fibroblast | 4 studies | 23% ± 6% | |
GABAergic interneuron | 3 studies | 21% ± 1% | |
retinal rod cell | 3 studies | 25% ± 5% | |
endothelial cell of lymphatic vessel | 3 studies | 22% ± 5% | |
transit amplifying cell | 3 studies | 46% ± 29% | |
adipocyte | 3 studies | 17% ± 1% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 1002.14 | 1445 / 1445 | 100% | 7.54 | 183 / 183 |
brain | 100% | 625.54 | 2636 / 2642 | 98% | 6.51 | 694 / 705 |
breast | 100% | 1047.79 | 459 / 459 | 98% | 7.49 | 1095 / 1118 |
stomach | 100% | 692.81 | 359 / 359 | 97% | 7.38 | 278 / 286 |
uterus | 100% | 1113.26 | 170 / 170 | 97% | 8.60 | 444 / 459 |
intestine | 100% | 997.96 | 966 / 966 | 96% | 6.82 | 508 / 527 |
skin | 100% | 1273.96 | 1809 / 1809 | 95% | 7.15 | 448 / 472 |
lung | 100% | 848.70 | 578 / 578 | 94% | 5.23 | 1083 / 1155 |
bladder | 100% | 1027.95 | 21 / 21 | 92% | 5.80 | 463 / 504 |
prostate | 100% | 821.31 | 245 / 245 | 90% | 3.76 | 453 / 502 |
pancreas | 98% | 440.38 | 323 / 328 | 89% | 3.38 | 158 / 178 |
thymus | 100% | 719.40 | 653 / 653 | 84% | 3.76 | 511 / 605 |
ovary | 100% | 1220.82 | 180 / 180 | 83% | 3.45 | 358 / 430 |
adrenal gland | 100% | 539.15 | 258 / 258 | 73% | 2.89 | 168 / 230 |
kidney | 100% | 477.74 | 89 / 89 | 71% | 2.86 | 641 / 901 |
liver | 85% | 225.49 | 193 / 226 | 36% | 1.41 | 146 / 406 |
adipose | 100% | 961.91 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 1003.80 | 1335 / 1335 | 0% | 0 | 0 / 0 |
muscle | 100% | 788.44 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 760.36 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 9.57 | 45 / 45 |
lymph node | 0% | 0 | 0 / 0 | 97% | 7.47 | 28 / 29 |
heart | 96% | 590.15 | 829 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 76% | 5.88 | 61 / 80 |
peripheral blood | 55% | 883.08 | 508 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0006303 | Biological process | double-strand break repair via nonhomologous end joining |
GO_0006281 | Biological process | DNA repair |
GO_0006269 | Biological process | DNA replication, synthesis of primer |
GO_0006273 | Biological process | lagging strand elongation |
GO_0006289 | Biological process | nucleotide-excision repair |
GO_0006260 | Biological process | DNA replication |
GO_0032479 | Biological process | regulation of type I interferon production |
GO_1904161 | Biological process | DNA synthesis involved in UV-damage excision repair |
GO_0006272 | Biological process | leading strand elongation |
GO_0006270 | Biological process | DNA replication initiation |
GO_0000731 | Biological process | DNA synthesis involved in DNA repair |
GO_0006271 | Biological process | DNA strand elongation involved in DNA replication |
GO_1902975 | Biological process | mitotic DNA replication initiation |
GO_0005730 | Cellular component | nucleolus |
GO_0005658 | Cellular component | alpha DNA polymerase:primase complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005635 | Cellular component | nuclear envelope |
GO_0016363 | Cellular component | nuclear matrix |
GO_0005829 | Cellular component | cytosol |
GO_0000785 | Cellular component | chromatin |
GO_0005634 | Cellular component | nucleus |
GO_0003887 | Molecular function | DNA-directed DNA polymerase activity |
GO_0003677 | Molecular function | DNA binding |
GO_0003682 | Molecular function | chromatin binding |
GO_0003688 | Molecular function | DNA replication origin binding |
GO_0003697 | Molecular function | single-stranded DNA binding |
GO_0019901 | Molecular function | protein kinase binding |
GO_0000166 | Molecular function | nucleotide binding |
GO_0008270 | Molecular function | zinc ion binding |
GO_0005515 | Molecular function | protein binding |
Gene name | POLA1 |
Protein name | DNA polymerase alpha catalytic subunit (EC 2.7.7.7) (DNA polymerase alpha catalytic subunit p180) DNA polymerase (EC 2.7.7.7) DNA polymerase alpha 1, catalytic subunit Alternative protein POLA1 |
Synonyms | POLA |
Description | FUNCTION: Catalytic subunit of the DNA polymerase alpha complex (also known as the alpha DNA polymerase-primase complex) which plays an essential role in the initiation of DNA synthesis. During the S phase of the cell cycle, the DNA polymerase alpha complex (composed of a catalytic subunit POLA1, a regulatory subunit POLA2 and two primase subunits PRIM1 and PRIM2) is recruited to DNA at the replicative forks via direct interactions with MCM10 and WDHD1. The primase subunit of the polymerase alpha complex initiates DNA synthesis by oligomerising short RNA primers on both leading and lagging strands. These primers are initially extended by the polymerase alpha catalytic subunit and subsequently transferred to polymerase delta and polymerase epsilon for processive synthesis on the lagging and leading strand, respectively. The reason this transfer occurs is because the polymerase alpha has limited processivity and lacks intrinsic 3' exonuclease activity for proofreading error, and therefore is not well suited for replicating long complexes. In the cytosol, responsible for a substantial proportion of the physiological concentration of cytosolic RNA:DNA hybrids, which are necessary to prevent spontaneous activation of type I interferon responses . . |
Accessions | A0A7I2V2V3 ENST00000677890.1 ENST00000672178.1 ENST00000379059.7 A0A5F9ZHW2 L8ECG9 ENST00000379068.8 A6NMQ1 P09884 |